Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lifecore Biomedical (LCBM) -- Ignore unavailable to you. Want to Upgrade?

To: Clouseau who wrote (2)	1/21/1999 12:05:00 AM
From: Mike	Respond to of 43

Lifecore announced the earnings that beat estimates. Expectations were for a profit of anywhere from 0.01-0.02 and actual was 0.04. Looking at the financials does not print as rosy of a picture. First I want to state that I am not a great financial guy. Looking over the earnings statement the major concern is that the HA division only had a 1% sales increase. This is with some International approvals of Intergel already in hand. In addition, shipments have continued to Alcon. This result is very disappointing. The major reason for the earnings was a decrease in expenses associated with R&D on the HA side. The other concern is that inventories on the HA side are building up. Inventories on the HA side now stand at over $13 million. One last concern is the cash on hand. We have decreased the cash on hand from over the $2M level to around $600K. Are we looking at a cash crunch and secondary offering? I dont know but I started this board a short time ago to complete due diligence on the stock. Looking for input from others. Good Luck, Mike